Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. (Nasdaq: ORCHESTRA) is a biomedical innovation company that accelerates high-impact medical device technologies to patients through strategic collaborations with leading global medical device manufacturers. The company operates a partnership-enabled business model designed to share the… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Orchestra BioMed Holdings, Inc. does
In the company’s own words
Orchestra BioMed Holdings, Inc. (Nasdaq: ORCHESTRA) is a biomedical innovation company that accelerates high-impact medical device technologies to patients through strategic collaborations with leading global medical device manufacturers. The company operates a partnership-enabled business model designed to share the risks and rewards of developing and commercializing innovative product candidates with established multinational partners rather than pursuing independent commercialization.
The company's flagship product candidates address major cardiovascular indications in large, well-established global markets. AVIM Therapy is a bioelectronic treatment for uncontrolled hypertension designed to reduce blood pressure through programmed cardiac pacing algorithms integrated into standard dual-chamber pacemakers. The company has an exclusive license and collaboration agreement with Medtronic for development and commercialization of AVIM Therapy in pacemaker-indicated patients, with the BACKBEAT global pivotal study currently enrolling patients. Virtue Sirolimus AngioInfusion Balloon is a drug-device combination product candidate for treating atherosclerotic artery disease, particularly in-stent restenosis, designed to deliver an extended-release sirolimus formulation without requiring balloon coating or permanent implants. The company recently initiated the Virtue Trial, a pivotal study comparing Virtue SAB to Boston Scientific's AGENT drug-coated balloon.
Orchestra BioMed's pipeline also includes Cardiac Neuromodulation Therapy for heart failure and potential applications of its proprietary SirolimusEFR formulation in additional indications. The company was formed in 2018 through the merger of Caliber Therapeutics and BackBeat Medical, combining their respective product development capabilities. In January 2023, Orchestra BioMed completed a business combination with Health Sciences Acquisitions Corporation 2, becoming a publicly traded company.
The company has secured significant partnerships and funding to support its development programs, including investments from Medtronic, Terumo Corporation, and Ligand Pharmaceuticals. Orchestra BioMed targets addressable markets exceeding $2.4 billion annually for AVIM Therapy in pacemaker-indicated hypertension patients and at least $10 billion for Virtue SAB across its targeted indications.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- NEW HOPE, PA
- Fiscal year end
- December
- CIK
- 1814114
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Orchestra BioMed Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Orchestra BioMed Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Orchestra BioMed Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Orchestra BioMed Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Orchestra BioMed Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”